



MINUTES

Utah Department of Health
Drug Utilization Review Board

Thursday, May 11, 2017
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Jennifer Brinton, M.D., Board Chair
Ben Berrett, Pharm.D.
Neal Catalano, Pharm.D.
Aesha Drozdowski, Pharm.D.
Holly Gurgle, Pharm.D.
Steve Lore, M.D.

Kim Michelson, D.D.S.
Kumar Shah, M.Sc., P.Eng.
Katherine Smith, Pharm.D.
Keith Tolman, M.D.
Susan Weinstein, M.D.
Eric Cannon, Pharm.D., FAMCP

Board Members Excused:

Mike Symond, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Sue Leong, RPh., Pharmacy Director
Susan Siegfried, M.D.
Bryan Larson, Pharm.D., P&T Manager
Robyn Seely, Pharm.D., DUR Manager
Andrea Rico, CPhT

Merelynn Berrett, R.N., PA
Heather Santacruz, R.N., PA
Alyssa Pitts, R.N., P.A.
John Curless, BCRP Bureau Director

Other Individuals Present:

Caroline Kicklighter, Novartis
Robert Nohavec, U of U
Anthony Richards, Alkermes
Mark Adams, Novo Nordisk
Vicki Frydrich, U of U

Charissa Anni, Johnson & Johnson
Joanne LaFleur, U of U
Cody Ball, SelectHealth
Lori Howarth, Bayer

Meeting conducted by: Jennifer Brinton, M.D.

1. **Welcome & Housekeeping:** Jennifer Brinton, M.D., opened the meeting and reminded everyone to sign the rosters.
2. **Review and Approval of February Minutes:** Board made a motion to Approve the minutes from February. Unanimous approval.
3. **Reconsideration of PA Criteria, Selzentry:**
 - a. **Information:**
 - b. **Public Comment:**
 - c. **Board Discussion:**
 - d. **Board Action:**
4. **Entresto nine month review:**

- a. **Information:** Robyn Seely said that the previously set criteria on this medication are working well with no problems.
 - b. **Public Comment:** Caroline Kicklighter spoke regarding the comparison of angiotensin converting enzyme inhibitors and angiotensin receptor blockers to Entresto requesting reconsideration of the criteria to use an angiotensin converting enzyme inhibitor or angiotensin receptor blocker prior to the use of Entresto. Caroline also discussed the paradigm studies regarding the use of a beta-patient population regardless of the use of a beta-adrenergic blocker. She requested that criterion be removed as well.
 - c. **Board Discussion:** Keith Tolman asked what the PA criteria was doing for our patient population. Robyn Seely stated that Entresto is expensive. Eric Cannon inquired as to how much Enalapril is being used by the Medicaid population today. Per Robyn Seely, that information is not available at the moment, but can be obtained.
 - d. **Board Action:** DUR Board motioned to revisit PA criteria on Entresto once utilization data is available. Unanimous approval.
5. **Movantik nine month review:**
- a. **Information:** Robyn Seely said that the previously set criteria on these medications is working well with no problems.
 - b. **Public Comment:** None
 - c. **Board Discussion:** None
 - d. **Board Action:** No change to PA criteria.
6. **Vivitrol:**
- a. **Information:** Valerie Gonzales presented a review of Vivitrol. She presented peer-reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
 - b. **Public Comment:**
 - 1. Anthony Richards presented information on the Opioid Epidemic and the use of Vivitrol. Neal Catalano inquired about the stability of Vivitrol. Per Anthony Richards, the medication has a short life, approximately 7 hours once it is mixed for administration.
 - 2. Robyn Seely read a letter regarding the use of Vivitrol from Robert Johnson at The Utah County Department of Drug and Alcohol Prevention and Treatment.
 - 3. Robyn Seely read a letter regarding the use of Vivitrol from Richard C. Arbogast at Odyssey House.
 - c. **Board Discussion:**
 - 1. Aesha Drozdowski clarified for the board there is no data indicating people who are opioid dependent may have a higher abuse potential.
 - 2. The board discussed the need to adjust the PA approval period to be reviewed more frequently to address adherence issues.
7. **Public Meeting Adjourned:** Jennifer Brinton adjourned the meeting.
8. **The next meeting scheduled for Thursday, June 08, 2017** Basal Insulins.